AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY24 results · Oct–Dec 2023
AstraZeneca Pharma India reported revenue from operations of ₹305.79 crore (up 22.4% from Q3 FY23) and net profit of ₹15.80 crore (down 46.1% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a standalone basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 305.79 | 249.81 | +22.4% | 311.07 | −1.7% |
| Other income | 9.66 | 7.20 | +34.2% | 8.37 | +15.4% |
| Total income | 315.45 | 257.00 | +22.7% | 319.44 | −1.3% |
| Profit before tax | 20.40 | 39.46 | −48.3% | 73.38 | −72.2% |
| Net profit for the period | 15.80 | 29.30 | −46.1% | 52.37 | −69.8% |
| EPS, basic (₹) | 6.32 | 11.72 | −46.1% | 20.95 | −69.8% |
| Net margin (%) | 5.2 | 11.7 | 16.8 |
Standalone
- Filed with BSE
- 09 Feb 2024, 14:46 IST
- Board meeting
- 08 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE